Building a scalable pipeline in high-impact markets
We leverage our unique product development expertise to unlock the full potential of existing medicines, minimizing clinical failure risks, and accelerating the delivery of innovative, value-added treatments.
GLCP-004-1
Central Nervous Diseases
Reformulation and development of a high-concentration intramuscular (IM) formulation of a known compound the treatment of Treatment-Resistant Schizophrenia (TRS)
GLCP-048-1
Stroke
Repurposing and development of an oral formulation of a known compound for the prevention of secondary stroke in high-risk patients, with low-bleeding risk and a novel mechanism of action
GLCP-092-1
Post Stroke Apathy
Reformulation and development of a known compound for the treatment of post-stroke apathy and aphasia​
​
GLCP-086-1
Stroke
Development of a novel formulation of a known compound for neuroprotection of ischemic stroke-induced brain damage in patients undergoing thrombectomy
GLCP-046-1
Stroke
Repurposing and development of an oral formulation of a known compound for neuroprotection of stroke-induced brain damage, with a focus on rapid administration
​
GLCP-063-1
Pain Management
Repurposing and development of a topical formulation of known compound for the prevention and treatment of Chemotherapy-Induced Peripheral Neuropathy (CIPN)
GLCP-008-1
Oncology
Redevelopment of an existing cancer medicine for relapsed/refractory acute myeloid leukemia, designed to reduce toxicity and overcome treament resistance.
​
GLCP-079-1
Infectious Diseases
Reformulation and development of high-dose, targeted formulation of a known compound for the treatment of drug-resistant
long infections
​
GLCP-003-1
Cardiovascular
Reformulation and development of an oral extended-release formulation of a known compound for the treatment of VT/VF and LQTS
​
Projects currently under active review:
GLCP-007-1 (pouchitis), GLCP-051-1 (endometriosis), GLCP-122-1 (cardiomyopathy), GLCP-124-1 (vascular malformations); GLCP-127-1 (oncology), GLCP-128-1 (atherosclerosis), GLCP-129-1 (psychiatric conditions), GLCP-132-1 (oncology), …
Strong focus on product innovation
Most of our value-added medicine (VAM) development programs originate from collaborations with prestigious universities, medical schools and smaller specialty pharma firms. In recent years, drug repurposing has indeed gained substantial traction due to its budget constraints and expedited development timelines, particularly compared to new NCE or biotech product development. However, reliance only on existing, commercially available dosage forms presents challenges, as protection through 'use patents' is rather limited. By incorporating a drug reformulation strategy, Galenicap unlocks the potential to create unique products with a robust intellectual property (IP) position that aligns perfectly with the new therapeutic indications being targeted.
Multidisciplinary screening process
Before embarking on new development programs, candidate projects undergo a thorough evaluation process. This includes the validation of clinical necessity and Target Product Profile, an assessment of technical feasibility, scrutiny of the IP landscape and market exclusivity, examination of the regulatory pathway, formulation of an appropriate go-to-market strategy, and exploration of opportunities for commercialization or partnerships. This comprehensive procedure involves close collaboration with external experts and insights from clinical KOLs. Furthermore, the evaluation process takes into account factors such as development costs, portfolio diversification, and a strong emphasis on addressing unmet clinical needs. The objective is to efficiently advance products, maintain a well-balanced portfolio, and prioritize impactful contributions to healthcare.
